

AA  
CONT.

does not contain tyrosines or tryptophans that can add to the fluorescence and complicate the analyses. This phage was generated before we understood the importance of iron for  $\alpha$ -synuclein biochemistry (hence, the binding site was not specifically targeted against iron binding). Even so, incubating a 10- fold excess of peptide with  $\alpha$ -synuclein reduces iron-induced  $\alpha$ -synuclein aggregation by 38%.

---

**In the Claims:**

---

A<sup>5</sup>

21. (Amended) The method of claim 20, wherein the peptide is selected from the group consisting of: WRQTRKD (SEQ ID NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3); RRRGMAI (SEQ ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO: 6); SLKRLPK (SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID NO: 9); HLYHHKT (SEQ ID NO: 10); THIIHPS (SEQ ID NO: 11); and MMMMMRL (SEQ ID NO: 12).

22. (Amended) The method of claim 21, wherein the peptide is selected from the group consisting of: THRLPSR (SEQ ID NO: 5); SLKRLPK (SEQ ID NO: 7); THIIHPS (SEQ ID NO: 11); and MMMMMRL (SEQ ID NO: 12).

23. (Amended) The method of claim 22, wherein the peptide is SLKRLPK (SEQ ID NO: 7).

---

A<sup>6</sup>

25. (Amended) The method of claim 24, whererin the agent is selected from the group consisting of: WRQTRKD (SEQ ID NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3); RRRGMAI (SEQ ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO: 6); SLKRLPK (SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID NO: 9); HLYHHKT (SEQ ID NO: 10); THIIHPS (SEQ ID NO: 11); and MMMMMRL (SEQ ID NO: 12).

26. (Amended) The method of claim 25, wherein the agent is selected from the group consisting of: THRLPSR (SEQ ID NO: 5); SLKRLPK (SEQ ID NO: 7); THIIHPS (SEQ ID NO: 11); and MMMMMRL (SEQ ID NO: 12).

A6  
cont.  
27. (Amended) The method of claim 26, wherein the peptide is  
SLKRLPK (SEQ ID NO: 7).

---

A7  
35. (Amended) The composition of claim 34, wherein the  
peptide is selected from the group consisting of: WRQTRKD (SEQ ID  
NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3); RRRGMAI (SEQ  
ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO: 6); SLKRLPK  
(SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID NO: 9);  
HLYHHKT (SEQ ID NO: 10); THIHHP (SEQ ID NO: 11); and MMMMRL (SEQ  
ID NO: 12).

36. (Amended) The composition of claim 35, wherein the  
peptide is selected from the group consisting of: THRLPSR (SEQ ID  
NO: 5); SLKRLPK (SEQ ID NO: 7); THIHHP (SEQ ID NO: 11); and MMMMRL  
(SEQ ID NO: 12).

37. (Amended) The composition of claim 36, wherein the  
peptide is SLKRLPK (SEQ ID NO: 7).

---

A8  
40. (Amended) The peptide of claim 39, wherein the peptide  
comprises a sequence selected from the group consisting of: WRQTRKD  
(SEQ ID NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3);  
RRRGMAI (SEQ ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO:  
6); SLKRLPK (SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID  
NO: 9); HLYHHKT (SEQ ID NO: 10); THIHHP (SEQ ID NO: 11); and  
MMMMRL (SEQ ID NO: 12).

41. (Amended) The peptide of claim 40, wherein the peptide  
comprises a sequence selected from the group consisting of: THRLPSR  
(SEQ ID NO: 5); SLKRLPK (SEQ ID NO: 7); THIHHP (SEQ ID NO: 11); and  
MMMMRL (SEQ ID NO: 12).

42. (Amended) The peptide of claim 41, which comprises the  
sequence SLKRLPK (SEQ ID NO: 7).

---